EDIT Stock Price, Editas Medicine Inc Quote, Chart

Market Summary

USD5.63-0.26

Market Closed

-4.41%

EDIT Alerts

Losses in recent quarter

EDIT Stock Price

View Fullscreen

EDIT RSI Chart

EDIT Valuation

Market Cap

463.0M

Price/Earnings (Trailing)

-2.79

Price/Sales (Trailing)

5.93

Price/Free Cashflow

-3.07

EDIT Price/Sales (Trailing)

EDIT Profitability

Return on Equity

-56.43%

Return on Assets

-37.73%

Free Cashflow Yield

-32.62%

EDIT Fundamentals

EDIT Revenue

Revenue (TTM)

78.1M

Rev. Growth (Yr)

818.74%

Rev. Growth (Qtr)

1.0K%

EDIT Earnings

Earnings (TTM)

-166.1M

Earnings Growth (Yr)

-26.34%

Earnings Growth (Qtr)

-228.23%

Breaking Down EDIT Revenue

Last 7 days

5.8%

Last 30 days

0.4%

Last 90 days

-30.9%

Trailing 12 Months

-40.2%

How does EDIT drawdown profile look like?

EDIT Financial Health

Current Ratio

4.6

EDIT Investor Care

Shares Dilution (1Y)

19.19%

Diluted EPS (TTM)

-2.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	22.8M	19.3M	24.6M	78.1M
2022	25.8M	31.8M	25.6M	19.7M
2021	91.5M	81.1M	24.5M	25.5M
2020	24.2M	32.6M	91.6M	90.7M
2019	30.1M	25.0M	14.4M	20.5M
2018	17.0M	21.2M	29.5M	31.9M
2017	5.9M	5.6M	11.0M	13.7M
2016	2.4M	5.7M	5.9M	6.1M
2015	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Editas Medicine Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	o'neill gilmore neil	sold	-732,884	9.4172	-77,824	ceo
Mar 04, 2024	mei baisong	sold	-191,425	9.4173	-20,327	svp, chief medical officer
Mar 02, 2024	lucera erick	acquired	-	-	61,266	evp, chief financial officer
Mar 02, 2024	burkly linda	acquired	-	-	39,855	evp, chief scientific officer
Mar 02, 2024	o'neill gilmore neil	acquired	-	-	275,125	ceo
Mar 02, 2024	mei baisong	acquired	-	-	89,815	svp, chief medical officer
Dec 05, 2023	eaton bruce	sold	-1,122	10.8972	-103	evp, cbo and cto
Nov 14, 2023	eaton bruce	sold	-5,705	8.2096	-695	evp, cbo and cto
Nov 07, 2023	eaton bruce	sold	-1,167	8.4	-139	evp, cbo and cto
Sep 06, 2023	eaton bruce	sold	-908	8.82	-103	evp, cbo and cto

Which funds bought or sold EDIT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-88.24	-7,396	698	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-0.82	-460,616	1,223,360	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.82	-248,014	551,729	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	added	700	49.00	59.00	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	reduced	-25.19	-228,970	277,530	0.02%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-87.39	-59,138	6,018	-%
May 15, 2024	Man Group plc	added	32.79	-21,212	755,111	-%
May 15, 2024	Engineers Gate Manager LP	reduced	-3.92	-274,827	652,878	0.02%
May 15, 2024	Cetera Advisor Networks LLC	sold off	-100	-114,236	-	-%
May 15, 2024	Graham Capital Management, L.P.	added	303	305,017	460,827	0.01%

Are Funds Buying or Selling EDIT?

Are funds buying EDIT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EDIT

No. of Funds

EDIT Alerts

Losses in recent quarter

Unveiling Editas Medicine Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	10.71%	8,760,151	SC 13G/A
Feb 14, 2024	deep track capital, lp	6.70%	5,473,086	SC 13G/A
Feb 13, 2024	vanguard group inc	10.36%	8,461,701	SC 13G/A
Jan 24, 2024	blackrock inc.	9.6%	7,838,969	SC 13G/A
Jan 10, 2024	state street corp	6.21%	5,069,543	SC 13G/A
Aug 04, 2023	deep track capital, lp	5.51%	4,493,416	SC 13G
Feb 09, 2023	vanguard group inc	10.00%	6,873,123	SC 13G/A
Feb 03, 2023	state street corp	13.41%	9,222,236	SC 13G/A
Jan 26, 2023	blackrock inc.	10.7%	7,338,742	SC 13G/A
Jan 20, 2023	blackrock inc.	10.7%	7,338,742	SC 13G/A

Recent SEC filings of Editas Medicine Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	144	Notice of Insider Sale Intent
May 14, 2024	4	Insider Trading
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 16, 2024	DEF 14A	DEF 14A
Apr 16, 2024	DEFA14A	DEFA14A
Apr 10, 2024	SC 13G/A	Major Ownership Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Editas Medicine Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Editas Medicine Inc News

Latest updates

Editas Medicine Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	60.00	5.00	3.00	10.00	7.00	0.00	6.00	7.00	12.00	6.00	0.00	6.00	11.00	63.00	11.00	6.00	12.00	4.00	2.00	2.00
Operating Expenses	-18.9%	68.00	84.00	55.00	47.00	61.00	70.00	58.00	61.00	58.00	54.00	45.00	56.00	63.00	77.00	54.00	42.00	52.00	52.00	38.00	38.00	33.00
S&GA Expenses	-100.0%	-	14.00	15.00	17.00	23.00	18.00	16.00	17.00	20.00	17.00	16.00	22.00	21.00	16.00	20.00	14.00	18.00	17.00	16.00	14.00	17.00
R&D Expenses	-29.9%	49.00	70.00	41.00	30.00	38.00	52.00	41.00	44.00	38.00	38.00	29.00	34.00	42.00	62.00	34.00	28.00	35.00	35.00	23.00	24.00	16.00
Net Income	-228.2%	-61.95	-18.87	-45.02	-40.29	-49.04	-60.74	-55.73	-53.45	-50.51	-41.44	-39.08	-55.26	-56.73	-62.50	8.00	-23.57	-37.72	-37.77	-32.94	-33.79	-29.25
Net Income Margin	-8.4%	-2.13*	-1.96*	-7.93*	-10.65*	-9.61*	-11.18*	-7.84*	-5.80*	-7.22*	-7.54*	-8.72*	-2.05*	-	-	-	-	-	-	-	-	-
Free Cashflow	-119.7%	-51.74	-23.55	-35.70	-40.04	-37.61	-42.90	-48.62	-38.48	-51.47	-37.43	-43.13	-41.66	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.8%	440	499	505	542	464	514	531	581	623	677	717	756	780	573	597	655	467	509	372	356	379
Current Assets	-10.3%	306	341	359	441	324	357	427	461	497	507	568	616	632	419	507	610	425	464	339	324	347
Cash Equivalents	-40.9%	73.00	124	83.00	221	129	142	215	173	215	207	264	342	359	144	283	490	235	240	106	212	160
Net PPE	10.2%	13.00	12.00	12.00	13.00	13.00	16.00	15.00	16.00	17.00	17.00	16.00	15.00	14.00	14.00	14.00	13.00	12.00	11.00	10.00	9.00	8.00
Liabilities	-2.7%	146	150	144	142	147	154	116	115	110	124	130	143	142	179	156	229	232	246	162	163	162
Current Liabilities	5.2%	66.00	63.00	59.00	55.00	57.00	60.00	42.00	36.00	37.00	47.00	51.00	66.00	64.00	58.00	55.00	68.00	69.00	60.00	67.00	73.00	41.00
Shareholder's Equity	-15.7%	294	349	360	400	317	361	415	465	513	554	587	613	638	394	441	427	235	262	210	193	217
Retained Earnings	-7.8%	-1,293	-1,200	-1,212	-1,200	-1,127	-1,078	-1,017	-961	-908	-857	-816	-777	-721	-665	-602	-610	-586	-549	-511	-478	-444
Additional Paid-In Capital	0.5%	1,588	1,580	1,574	1,570	1,447	1,442	1,436	1,430	1,423	1,412	1,403	1,391	1,360	1,059	1,044	1,037	821	812	721	672	662
Shares Outstanding	0.6%	82.00	82.00	82.00	82.00	69.00	69.00	69.00	69.00	68.00	68.00	68.00	68.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	671	-	-	-	634	-	-	-	1,147	-	-	-	1,840	-	-	-	1,222	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-124.2%	-49,872	-22,240	-35,459	-38,711	-35,768	-42,273	-48,004	-37,845	-49,227	-34,582	-40,785	-38,957	-49,479	-40,100	-54,801	-30,856	-54,086	41,024	-26,884	-25,806	-29,003
Share Based Compensation	41.9%	7,585	5,345	4,731	5,215	4,507	5,364	5,881	6,618	11,431	7,657	10,012	13,526	12,204	5,673	5,846	5,417	6,220	6,336	6,559	6,493	7,855
Cashflow From Investing	-107.6%	-4,745	62,840	-102,820	12,982	23,267	-27,528	89,227	-4,002	56,371	-22,840	-39,661	4,791	3,244	-108,894	-152,265	74,173	46,464	7,818	-122,302	76,110	50,626
Cashflow From Financing	-62.6%	192	514	-	117,525	-	619	80.00	367	218	1,057	2,496	17,082	261,471	9,100	822	211,153	3,047	84,569	43,353	2,369	1,533

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EDIT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration and other research and development revenues	$ 1,135	$ 9,851
Revenue type	Service [Member]	Service [Member]
Operating expenses:
Research and development	$ 48,787	$ 37,804
General and administrative	19,339	23,008
Total operating expenses	68,126	60,812
Operating loss	(66,991)	(50,961)
Other income, net:
Other income (expense), net	6	(1,584)
Interest income, net	5,035	3,509
Total other income, net	5,041	1,925
Net loss	$ (61,950)	$ (49,036)
Net loss per share, basic (in dollars per share)	$ (0.76)	$ (0.71)
Net loss per share, diluted (in dollars per share)	$ (0.76)	$ (0.71)
Weighted-average common shares outstanding, basic (in shares)	81,938,839	68,924,180
Weighted-average common shares outstanding, diluted (in shares)	81,938,839	68,924,180

EDIT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 69,227	$ 123,652
Marketable securities	226,944	199,459
Accounts receivable	245	10,187
Prepaid expenses and other current assets	9,139	7,531
Total current assets	305,555	340,829
Marketable securities	80,605	104,024
Property and equipment, net	13,257	12,032
Right-of-use assets	31,443	33,680
Restricted cash and other non-current assets	9,487	8,588
Total assets	440,347	499,153
Current liabilities:
Accounts payable	7,966	8,269
Accrued expenses	31,481	34,563
Deferred revenue, current	14,684	8,221
Operating lease liabilities	12,356	12,164
Total current liabilities	66,487	63,217
Operating lease liabilities, net of current portion	21,783	24,372
Deferred revenue, net of current portion	54,204	60,667
Other non-current liabilities	3,473	1,800
Total liabilities	145,947	150,056
Stockholders’ equity
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 82,234,951 and 81,767,263 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	8	8
Additional paid-in capital	1,588,018	1,580,241
Accumulated other comprehensive (loss) income	(326)	198
Accumulated deficit	(1,293,300)	(1,231,350)
Total stockholders’ equity	294,400	349,097
Total liabilities and stockholders’ equity	$ 440,347	$ 499,153

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

CEO	Dr. Gilmore O'Neill
WEBSITE	editasmedicine.com
INDUSTRY	Biotechnology
EMPLOYEES	226

Editas Medicine Inc Frequently Asked Questions

What is the ticker symbol for Editas Medicine Inc? What does EDIT stand for in stocks?

EDIT is the stock ticker symbol of Editas Medicine Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Editas Medicine Inc (EDIT)?

As of Fri May 17 2024, market cap of Editas Medicine Inc is 463 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EDIT stock?

You can check EDIT's fair value in chart for subscribers.

What is the fair value of EDIT stock?

You can check EDIT's fair value in chart for subscribers. The fair value of Editas Medicine Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Editas Medicine Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EDIT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Editas Medicine Inc a good stock to buy?

The fair value guage provides a quick view whether EDIT is over valued or under valued. Whether Editas Medicine Inc is cheap or expensive depends on the assumptions which impact Editas Medicine Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EDIT.

What is Editas Medicine Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EDIT's PE ratio (Price to Earnings) is -2.79 and Price to Sales (PS) ratio is 5.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EDIT PE ratio will change depending on the future growth rate expectations of investors.